JO
SLXP

John Overdeck’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

John Overdeck’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-14,225
Closed -$2.22M – 2522
2014
Q3 		$2.22M Sell
14,225
-84,318
-86% -$12.2M 0.01% 839
2014
Q2 		$12.2M Sell
98,543
-198,743
-67% -$22M 0.05% 436
2014
Q1 		$30.8M Buy
297,286
+228,644
+333% +$23.4M 0.17% 158
2013
Q4 		$6.17M Buy
+68,642
New +$5.47M 0.03% 566
2013
Q3 		– Sell
-360,885
Closed -$23.9M – 2322
2013
Q2 		$23.9M Buy
+360,885
New +$20.6M 0.17% 170

Other funds holding SLXP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

John Overdeck's SLXP Position: Q4 2014 in Review

John Overdeck sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 14,225 shares — an estimated $2.22M sold.

John Overdeck first reported a position in SLXP in Q2 2013 and held it in 5 quarters. The position peaked at $30.8M in Q1 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • John Overdeck reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • John Overdeck sold 14,225 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $2.22M.
  • John Overdeck first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 5 quarters.
  • John Overdeck's SALIX PHARMACEUTICALS LTD DEL position peaked at $30.8M in Q1 2014.
  • 346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Two Sigma Investments's 13F filing for Q4 2014, filed 17 Feb 2015.